was started as was highly active antiretroviral therapy with emtricitabine/tenofovir disoproxil fumarate combination once daily along with efavirenz once daily. At the 4-month follow-up, the patient did not show any sign of recurrence or spreading of KS.
To our knowledge, these are the first reports of patients responding to a topical beta-blocker. KS usually develops in the later stages of HIV/AIDS; only rarely today is KS a presenting feature of HIV infection. Highly active antiretroviral therapy might have played a role in maintaining the remission of the KS lesion treated with timolol, particularly in avoiding the onset of newly spread lesions; indeed, it is known that in patients on highly active antiretroviral therapy, KS lesions may regress depending on the degree of restoration of the immune system. 4 Nonetheless, the therapeutic effect of the topical beta-blocker in our case was evident, as no other drugs were administered in the first 6 weeks.
Our case series confirms and adds to the mounting evidence of the efficacy of topical betablockers on different forms of KS. To the Editor: Hidradenitis suppurativa (HS) is a chronic, inflammatory, recurrent, and debilitating skin disease of the hair follicle that is characterized by painful, deep-seated inflamed nodules and fistulous tracts in most commonly, axillae, inguinal, and anogenital regions.
1 HS usually presents after puberty and predominately occurs in women with a female-to-male ratio of 3:1. The influence of hormones has been suspected in women with HS for more than 60 years yet has not been proven. 2 To date, few studies have described the influence of menses and pregnancy on HS symptoms, with deterioration during menses and amelioration during pregnancy being most frequently reported. 3, 4 However, these studies are limited by a relatively small sample size and many are dated, with more than half of the studies being published between 1986 and 1996. Moreover, the 2 most recent studies did not report on both menses and pregnancy.
We conducted a survey-based cross-sectional study to assess the influence of menses and pregnancy on HS symptoms in the Department of Dermatology at Erasmus University Medical Center (Rotterdam, The Netherlands). One hundred eightysix subjects answered the question on the influence of menses, 96 on pregnancy, and 75 on both (Table I) . Of the 186 respondents, 43% reported a deterioration of HS around menses, but 53.8% reported no change in symptoms. In 30.2% of subjects, pregnancy resulted in an amelioration of symptoms, while 53.1% reported no effect on symptoms. An amelioration during pregnancy was more frequently reported by subjects who experienced a deterioration during menses than by subjects who with no effect or an amelioration of HS symptoms perimenstrually (P ¼ .01). No correlation was found between Hurley stage and the course of perimenstrual symptoms (P ¼ .39) or symptoms during pregnancy (P ¼ .97). Furthermore, there was no correlation between body mass index and the severity of HS symptoms during menses or pregnancy (respectively, P ¼ .49, P ¼ .26).
The results of the previous smaller studies investigating the prevalence of perimenstrual flares and change of symptoms during pregnancy are in line with our findings. A flare of HS symptoms around menses was most frequently reported, by 44% to 63% of women. 3, 4 An amelioration of symptoms during pregnancy was most often described, namely in 20% to 83% of subjects.
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A major strength of our study is the relatively large sample size compared with previous studies. However, our survey-based study is limited by recall bias and a lack of information on the influence of reproductive elements (eg, menarche, menopause) or the use of hormonal contraceptives on the course of HS symptoms. Notwithstanding, the results provide additional clinical relevant insight into the course of symptoms in women with HS.
In conclusion, this study suggests a significant correlation between perimenstrual deterioration of HS symptoms and amelioration during pregnancy. This correlation could be explained from a hormonal perspective in that estrogen has been shown to inhibit proinflammatory Th1 and Th17 cytokines and thus favors an immunosuppressive environment. 5 Nonetheless, a substantial subset of women have no alteration of HS disease course perimenstrually or during pregnancy.
Interleukin 6 and high-sensitivity C-reactive protein are potential predictive markers of response to infliximab in hidradenitis suppurativa See related works on pages 54 and 155
To the Editor: The treatment of hidradenitis suppurativa (HS) remains highly challenging. Several studies have shown that antietumor necrosis factor (TNF) antibodies, such as those in infliximab (IFX) or adalimumab, clinically reduce disease activity in some cases of HS.
1 Adalimumab has shown its superiority against placebo in 2 prospective randomized trials. 1 Nevertheless, their efficacy (in this condition) is inconsistent. Identifying predictive markers of response is, thus, of strong interest. The objective of this prospective pilot study was to determine if the baseline inflammatory profile of patients with HS could predict the response to treatment with IFX.
Patients with moderate to severe HS (defined as Hurley stage II or III for at least 6 months) were enrolled, after giving their signed informed consent (institutional review board approval waived), and were treated with IFX (5 mg/kg) on weeks 0, 2, 6, and 14. The serum levels of the following inflammatory cytokines were measured before treatment and before each infusion: TNF-, interleukin (IL)-1, IL-6, and high-sensitivity (hs) C-reactive protein (CRP). All patients were carefully clinically evaluated for other causes that could increase CRP levels and, if Values as mean 6 SD or N (%). *Positive family history in first and second degree relatives. y Missing n ¼ 1 in menses group. z Missing n ¼ 1 in both groups.
x A significant correlation between amelioration during pregnancy and deterioration perimenstrually (Fisher's exact test).
